Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90

Journal of Medicinal Chemistry

Volumn 48, Issue 8, 2005, Pages 2892-2905

  Llauger, Laura ^a   He, Huazhong ^a   Kim, Joungnam ^a   Aguirre, Julia ^a   Rosen, Neal ^a   Peters, Ulf ^a   Davies, Peter ^b   Chiosis, Gabriela ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 SULFANYLADENINE DERIVATIVE; 8 SULFONYLADENINE DERIVATIVE; 8 SULFOXYLADENINE DERIVATIVE; 9 (PENT 4 YNYL) 8 (6 BROMOBENZO[1,3]DIOXOL 5 YLSULFANYL)ADENINE; ADENINE DERIVATIVE; CHAPERONE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PURINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; KIDNEY PROXIMAL TUBULE; MITOSIS INHIBITION; POLARIZATION; STRUCTURE ACTIVITY RELATION; TUMOR CELL;

ADENINE; ANIMALS; ANTINEOPLASTIC AGENTS; BINDING, COMPETITIVE; CELL LINE; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONES; SULFOXIDES;

EID: 17444416142     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm049012b     Document Type: Article

References (44)

1. (a) Wegele, H.; Muller, L.; Buchner, J. Hsp70 and Hsp90-a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 2004, 151, 1-44.
2. (b) Mosser, D. D.; Morimoto, R. I. Molecular chaperones and the stress of oncogenesis. Oncogene 2004, 23, 2901-2918.
3. (c) Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; Fritz, L. C.; Burrows, F. J. Therapeutic and diagnostic implications of Hsp90 activation. Trends Mol. Med. 2004, 10, 283-290.
4. (d) Neckers, L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol. Med. 2002, 8, S55-S61.
5. (e) Workman, P.; Maloney, A. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24.
6. (a) Sausville, E. A.; Tomaszewski J. E.; Ivy, P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 2003, 3, 377-383.
7. (b) Solit, D. Phase 1 pharmacokinetic and pharmacodynamic trial of docetaxel and 17AAG (17-allylamino-17-demethoxygeldanamycin). Presented at the Annual Meeting of ASCO, June 3-8, 2004, New Orleans, LA, (Abstract 3032).
8. Soga, S.; Shiotsu, Y.; Akinaga, S.; Sharma, S. V. Development of radicicol analogues. Curr. Cancer Drug Targets 2003, 3, 359-369.
9. Chiosis, G.; Lucas, B.; Huezo, H.; Solit, D.; Basso, A.; Rosen, N. Development of purine-scaffold small molecule inhibitors of Hsp90. Curr. Cancer Drug Targets 2003, 3, 363-368.
10. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; Sepp-Lorenzino, L.; Rosen N. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells. Chem. Biol. 2001, 8, 289-299.
11. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen N. Development of a Purine-based Novel Class of Hsp90 Binders That Inhibit the Proliferation of Cancer Cells and Induce the Degradation of Her2 Tyrosine Kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
12. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; He, H.; Rosen N.; Spampinato, C.; Modrich, P.; Chiosis, G. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90, Chem. Biol. 2004, 11, 787-797.
13. (a) Dymock, B.; Barril, X.; Beswick, M.; Collier, A.; Davies, N.; Drysdale, M.; Fink, A.; Fromont, C.; Hubbard, R. E.; Massey, A.; Surgenor, A.; Wright, L. Adenine derived inhibitors of the molecular chaperone HSP90-SAR explained through multiple X-ray structures. Bioorg. Med. Chem. Lett. 2004, 14, 325-328.
14. (b) Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; Beswick, M.; Drysdale, M.; Collier, A.; Massey, A.; Davies, N.; Fink, A.; Fromont, C.; Aherne, W.; Boxall, K.; Sharp, S.; Workman, P.; Hubbard, R. E. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem Biol. 2004, 6, 775-785.
15. Kasibhatla, S. R.; Hong, K.; Zhang, L.; Biamonte, M. A.; Boehm, M. F.; Shi, J.; Fan, J. PCT Int. Appl. WO 2003037860, 2003.
16. (a) Naidis, F. B.; Kolesova, M. B.; Aleksander, K. L.; Smirnova, N. V.; Pernikoza, V. G. Method of obtaining 8-bromoadenine. Izobreteniya 1995, 1, 242-243.
17. 15N NMR Spectroscopy and Theoretical Calculations. J. Org. Chem. 2001, 66, 5463-5481.
18. (a) Bates, C. G.; Gujadhur, R. T.; Venkataraman, D. A general method for the formation of aryl-sulfur bonds using copper(I) catalysts. Org. Lett. 2002, 4, 2803-2806.
19. (b) Gwong, F. Y.; Buchwald, L. A general, efficient, and inexpensive catalyst system for the coupling of aryl iodides and thiols. Org. Lett. 2002, 4, 3517-3520.
20. (c) He, H.; Llauger, L.; Rosen, N.; Chiosis, G. General Method for the Synthesis of 8-Arylsulfanyl Adenine Derivatives, J. Org. Chem. 2004, 69, 3230-3232.
21. (a) Leuckart, R. J. Prakt. Chem. 1890, 41, 179.
22. (b) Tarbell, D. S.; Fukushima, D. K. m-Thiocresol. Org. Synth. 1947, 27, 81.
23. (a) Mitsunobu, O. The use of diethyl azodicarboxylate and triphenylphosphine in synthesis and transformation of natural products. Synthesis 1981, 1, 1-28.
24. (b) Lucas, B.; Rosen, N.; Chiosis, G. Facile synthesis of 9-Alkyl-8-benzyl-9H-purin-6-ylamine Derivatives. J. Comb. Chem. 2001, 3, 518-520.
25. Tipson, R. S. On esters of p-toluenesulfonic acid. J. Org. Chem. 1944, 9, 235-241.
26. 2 (or TBHP). Tetrahedron, 1999, 55, 11127-11142.
27. Castanet, A.-S.; Colobert, F.; Broutin, P.-E. Mild and regioselective iodination of electron-rich aromatics with N-iodosuccinimide and catalytic trifluoroacetic acid. Tetrahedron Lett. 2002, 43, 5047-5048.
28. VanAllan, J. A.; Deacon, B. D. 2-Mercaptobenzimidazole. Org. Synth. 1945, 4, 569.
29. (a) Fukuhara, T.; Yoneda, N.; Suzuki, A. A facile preparation of fluoropyridines from Aminopyridines via diazotization and fluorodediazoniation in HF or HF-pyridine solutions. J. Fluorine Chem. 1988, 38, 435-438.
30. (b) Thompson, A. M.; Showalter, H. D. H.; Denny, W. A. Synthesis of 7-substituted 3-aryl-1,6-naphthyridin-2-amines and 7-substituted 3-aryl-1,6-naphthyridin-2(1H)-ones via diazotization of 3-aryl-1,6- naphthyridine-2,7-diamines. J. Chem. Soc., Perkin Trans, 1 2000, 1843-1852.
31. Camaioni, E.; Costanzi, S.; Vittori, S.; Volpini, R.; Klotz, K.-N.; Cristalli, G. New substituted 9-alkylpurines as adenosine receptor ligands. Bioorg. Med. Chem. 1998, 6, 523-533.
32. Llauger, L.; He, H.; Chiosis, G. Synthesis of 8-arylsulfoxyl/ sulfonyl adenines. Tetrahedron Lett. 2004, 45, 9549-9552.
33. 1 Synthesis of N-Triphenylphosphoranylidene Nucleosides by Mitsunobu Reaction. A Novel Protecting Group for Primary Amines of Nucleosides. Tetrahedron Lett. 1995, 36, 7881-7884.
34. Kropp, P. J.; Breton, G. W.; Fields, J. D.; Tung, J. C.; Loomis, B. R. Surface-Mediated Reactions. 8. Oxidation of Sulfides and Sulfoxides with tert-Butyl Hydroperoxide and OXONE. J. Am. Chem. Soc. 2000, 122, 4280-4285.
35. (a) Llauger-Bufi, L.; Felts, S. J.; Huezo, H.; Rosen, N.; Chiosis, G. Synthesis of novel fluorescent probes for the molecular chaperone Hsp90. Bioorg. Med. Chem. Lett. 2003, 13, 3975-3978.
36. (b) Kim, J.; Felts, S.; Llauger, L.; He, H.; Huezo, H.; Rosen, N.; Chiosis, G. Development of a fluorescence polarization assay for the molecular chaperone Hsp90. J. Biomol. Screen. 2004, 9, 375-381.
37. Mimnaugh, E. G.; Chavany, C.; Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 1996, 271, 22796-22801.
38. Srethapakdi, M.; Liu, F.; Tavorath, R.; Rosen, N. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 2000, 60, 3940-3946.
39. Huezo, H.; Vilenchik, M.; Rosen, N.; Chiosis, G. Microtiter cell-based assay for detection of agents that alter cellular levels of Her2 and EGFR. Chem. Biol. 2003, 10, 629-634.
40. Roberge, M.; Cinel, B.; Anderson, H. J.; Lim, L.; Jiang, X.; Xu, L.; Bigg, C. M.; Kelly, M. T.; Andersen, R. J. Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts. Cancer Res. 2000, 60, 5052-5058.
41. (a) Vincent, I.; Zheng, J. H.; Dickson, D. W.; Kress, Y.; Davies, P. Mitotic phosphoepitopes precede paired helical filaments in Alzheimer's disease. Neurobiol. Aging. 1998, 19, 287-296.
42. (b) Goedert, M.; Jakes, R.; Crowther, R. A.; Cohen, P.; Vanmechelen, E.; Vandermeeren, M.; Cras, P. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer's disease: identification of phosphorylation sites in tau protein. Biochem. J. 1994, 301, 871-877.
43. Kelland, L. R.; Sharp, S. Y.; Rogers, P. M.; Myers, T. G.; Workman, P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino-17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J. Natl. Cancer Inst. (Bethesda) 1999, 91, 1940-1949.
44. Offer, J.; Boddy, C. N. C.; Dawson, P. E. Extending Synthetic Access to Proteins with a removable Acyl Transfer Auxiliary. J. Am. Chem. Soc. 2002, 124, 4642-4646.